LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds
LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with USD 19 million.
The two-year-old Canadian biotech will utilize series A to bring a lineup of SGK1 inhibitors through phase 1 clinical studies. LQTT has a portfolio of in-licensed compounds from Sanofi that prohibit serum/glucocorticoid-regulated kinase 1, or SGK1.
That kinase plays a role in inappropriate sodium regulation, a hallmark of arrhythmias like Long QT Syndrome. The company's founders have confirmed...
